Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
ConclusionsAlthough the metformin plus temozolomide regimen was well tolerated, it did not confer a clinical benefit in patients with recurrent or refractory GBM.Trial registration NCT03243851, registered August 4, 2017.
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Clinical Trials | Fortamet | Glioma | Hormones | Metformin | Statistics | Study | Temodar